Pacira(PCRX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, the company achieved $726 million in revenue, marking a significant increase compared to previous years, with the highest gross margins in its history at 80% for Q4 2025, up from 79% in Q4 2024 [5][19] - The fourth quarter sales for EXPAREL increased to $155.8 million from $147.7 million in 2024, reflecting a volume growth of approximately 7% [18] - Non-GAAP R&D expenses rose to $34.4 million in Q4 2025 from $22.0 million in the previous year, while SG&A expenses increased to $91.9 million from $70.6 million [20] Business Line Data and Key Metrics Changes - EXPAREL showed solid performance with volume-based growth driven by increased education and awareness, payer adoption, and demand across care sites [7][8] - ZILRETTA sales remained flat at $33 million in Q4 2025 compared to 2024, while iovera sales grew to $7 million from $6.5 million [18] Market Data and Key Metrics Changes - The company ended 2025 with 102 million lives covered outside the surgical bundle, indicating a significant shift in payer policies [15] - The strategic focus on expanding payer coverage in key markets resulted in over 7% volume growth in these areas compared to 2024 [15][16] Company Strategy and Development Direction - The company is committed to its 5x30 strategy, aiming to help 3 million patients annually by 2030, with a focus on expanding its pipeline and strategic partnerships [5][7] - A significant partnership with LG Chem was announced to commercialize EXPAREL in select Asia Pacific countries, with revenues expected to begin in 2027 [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting a clear strategic direction and improved operational efficiencies [4][12] - The company anticipates steady top-line growth in 2026, with revenue guidance set between $745 million and $770 million [22] Other Important Information - The company executed $150 million in stock repurchases, reducing outstanding shares to approximately 41 million [21] - The company is focused on maintaining a disciplined approach to capital deployment while investing in growth and innovation [21] Q&A Session Summary Question: What constitutes a clinically meaningful signal for the OA readout? - Management clarified that the primary focus of the study is safety, with secondary endpoints related to pain, stiffness, and function being evaluated [28][30] Question: What factors could lead to higher or lower EXPAREL sales guidance? - Management indicated that the steady growth observed in 2025 positions the company well for 2026, with potential market dynamics influencing sales [37][39] Question: What headwinds affected ZILRETTA's performance in 2025? - Management noted that prioritization of EXPAREL and restructuring of sales forces impacted ZILRETTA sales, but they expect growth in 2026 with a fully trained J&J sales team [58][60] Question: Will unexpected business development costs continue? - Management acknowledged that such costs may occur but emphasized a disciplined approach to investments and potential accretive deals [64][66]